Decoy Therapeutics (DCOY) Gains from Investment Securities (2019 - 2022)
Decoy Therapeutics (DCOY) posted quarterly Gains from Investment Securities of -$1884.0 for Q4 2022, up 95.23% year-over-year from -$965.02 in Q4 2021, and down 462.39% quarter-over-quarter from -$335.0 in Q3 2022.
Decoy Therapeutics (DCOY) Gains from Investment Securities (2019 - 2022) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Gains from Investment Securities for 4 consecutive years, with -$1884.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Gains from Investment Securities rose 95.23% year-over-year to -$1884.0; the TTM figure through Dec 2022 stood at -$14454.0 (up 67.66% YoY), while the FY2025 annual figure was -$6540.0, changed N/A from the prior year.
- Gains from Investment Securities fell to -$1884.0 in Q4 2022 per DCOY's latest filing, from -$335.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $62635.0 in Q2 2020 and bottomed at -$1.1 million in Q3 2019.
- Historically, Gains from Investment Securities has averaged -$116359.4 across 4 years, with a median of -$7750.0 in 2021.
- On a YoY basis, Gains from Investment Securities climbed as much as 116.27% in 2021 and fell as far as 665.16% in 2021.
- Decoy Therapeutics' Gains from Investment Securities stood at -$180485.0 in 2019, then jumped by 103.87% to $6987.0 in 2020, then tumbled by 665.16% to -$39488.0 in 2021, then soared by 95.23% to -$1884.0 in 2022.
- Business Quant data shows DCOY's Gains from Investment Securities at -$1884.0 in Q4 2022, -$335.0 in Q3 2022, and -$6427.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -1,884.00 |
| Dec 31, 2022 | -1,884.00 |
| Sep 30, 2022 | -335.00 |
| Sep 30, 2022 | -335.00 |
| Jun 30, 2022 | -6,427.00 |
| Jun 30, 2022 | -6,427.00 |
| Mar 31, 2022 | -5,808.00 |
| Mar 31, 2022 | -5,808.00 |
| Dec 31, 2021 | -39,488.00 |
| Dec 31, 2021 | -39,488.00 |
| Sep 30, 2021 | -9,073.00 |
| Sep 30, 2021 | -9,073.00 |
| Jun 30, 2021 | -42,186.00 |
| Jun 30, 2021 | -42,186.00 |
| Mar 31, 2021 | 46,054.00 |
| Mar 31, 2021 | 46,054.00 |
| Dec 31, 2020 | 6,987.00 |
| Dec 31, 2020 | 6,987.00 |
| Sep 30, 2020 | -45,103.00 |
| Sep 30, 2020 | -45,103.00 |